These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
10. Targeting vascular endothelial growth factor (VEGF) for anti-tumor therapy, by anti-VEGF neutralizing monoclonal antibodies or by VEGF receptor tyrosine-kinase inhibitors. Schlaeppi JM; Wood JM Cancer Metastasis Rev; 1999; 18(4):473-81. PubMed ID: 10855790 [TBL] [Abstract][Full Text] [Related]
11. Emerging therapies targeting tumor vasculature in multiple myeloma and other hematologic and solid malignancies. Podar K; Anderson KC Curr Cancer Drug Targets; 2011 Nov; 11(9):1005-24. PubMed ID: 21933109 [TBL] [Abstract][Full Text] [Related]
12. Inhibition of vascular endothelial growth factor-associated tyrosine kinase activity with SU5416 blocks sprouting in the microvascular endothelial cell spheroid model of angiogenesis. Haspel HC; Scicli GM; McMahon G; Scicli AG Microvasc Res; 2002 May; 63(3):304-15. PubMed ID: 11969307 [TBL] [Abstract][Full Text] [Related]
13. Measuring VEGF-Flk-1 activity and consequences of VEGF-Flk-1 targeting in vivo using intravital microscopy: clinical applications. Vajkoczy P; Thurnher A; Hirth KP; Schilling L; Schmiedek P; Ullrich A; Menger MD Oncologist; 2000; 5 Suppl 1():16-9. PubMed ID: 10804086 [TBL] [Abstract][Full Text] [Related]
14. Angiogenesis inhibition in solid tumors. Rosen LS Cancer J; 2001; 7 Suppl 3():S120-8. PubMed ID: 11779082 [TBL] [Abstract][Full Text] [Related]
15. The pathophysiologic role of VEGF in hematologic malignancies: therapeutic implications. Podar K; Anderson KC Blood; 2005 Feb; 105(4):1383-95. PubMed ID: 15471951 [TBL] [Abstract][Full Text] [Related]
16. A targeted approach for antiangiogenic therapy of metastatic human colon cancer. Ellis LM Am Surg; 2003 Jan; 69(1):3-10. PubMed ID: 12575772 [TBL] [Abstract][Full Text] [Related]
17. Differential drug class-specific metastatic effects following treatment with a panel of angiogenesis inhibitors. Chung AS; Kowanetz M; Wu X; Zhuang G; Ngu H; Finkle D; Komuves L; Peale F; Ferrara N J Pathol; 2012 Aug; 227(4):404-16. PubMed ID: 22611017 [TBL] [Abstract][Full Text] [Related]
18. Role of angiogenesis inhibitors in acute myeloid leukemia. Fiedler W; Staib P; Kuse R; Dührsen U; Flasshove M; Cavalli F; Hossfeld DK; Berdel WE Cancer J; 2001; 7 Suppl 3():S129-33. PubMed ID: 11779083 [TBL] [Abstract][Full Text] [Related]
19. von Hippel-Lindau syndrome: target for anti-vascular endothelial growth factor (VEGF) receptor therapy. Harris AL Oncologist; 2000; 5 Suppl 1():32-6. PubMed ID: 10804089 [TBL] [Abstract][Full Text] [Related]
20. Angiogenic and lymphangiogenic molecules in hematological malignancies. Orpana A; Salven P Leuk Lymphoma; 2002 Feb; 43(2):219-24. PubMed ID: 11999550 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]